Collegium’s Charts Fail to Forecast the Next Move

Sparse signal coverage renders price patterns powerless

COLL Collegium Pharmaceutical, Inc.

In this report

01

Price Signals vs Fundamentals

Momentum, volatility, relative strength → revenue, margin, ROE

→

02

Institutional Flow Impact

Ownership changes vs price returns — leading or lagging?

→

03

Earnings Surprise Patterns

Beat rates, pre-drift, announcement reactions, post-drift

→

04

Multi-Signal Integration

Signal coverage and data quality assessment

→

05

Signal Discovery Summary

Top signals, cross-company patterns, monitoring recommendations

→

Price Signals vs Fundamental Outcomes

Collegium Pharmaceutical, Inc. (COLL) — Signal-Fundamental Correlation

How to read this section: We test whether three price-based signals — 12-month momentum (trailing stock return), realized volatility (annualized standard deviation of daily returns), and relative strength (stock return minus S&P 500 return) — predict next-quarter fundamental outcomes: revenue growth, operating margin change, and ROE change (all year-over-year to remove seasonality). Each cell shows the Pearson correlation (r) between signal at quarter Q and outcome at quarter Q+1. Values closer to +1 or −1 indicate stronger predictive relationships. “n” is the number of quarterly observations.

The examination of price-based technical signals—12‑month momentum, realized volatility, and relative strength—against fundamental outcomes for Collegium Pharmaceutical (COLL) over a 45‑quarter horizon reveals an absence of statistically meaningful predictive relationships. Across all three fundamentals examined—revenue growth, margin change, and ROE change—the correlation coefficients remain modest (|r| ≤ 0.171) and none achieve conventional significance thresholds (p < 0.05). Consequently, the data do not support a claim that any of these price signals reliably forecast short‑term fundamental shifts for this business within the sample period.

No price signal reaches statistical significance (p<0.05) for predicting revenue growth, margin change, or ROE change for COLL.
The strongest observed correlation is realized volatility vs. margin change at r=-0.171 (p=0.291), which remains weak and non‑significant.
All examined signals have |r| < 0.2, well below the threshold for a notable relationship (|r|≥0.4).
Sample size of 39‑40 observations limits statistical power, contributing to wide confidence intervals around each estimate.

Limitations: Small sample (≈40 quarters) reduces the ability to detect modest effects and inflates uncertainty in r‑values. Correlations do not imply causation; observed links may be driven by external market regimes rather than intrinsic price‑fundamental dynamics. The analysis covers a single firm, so any identified pattern cannot be generalized across the broader pharmaceutical sector.

COLL

For Collegium Pharmaceutical, 12‑month momentum shows weak positive correlations with revenue growth (r= N/A, insufficient data), margin change (r=0.140, p=0.388) and ROE change (r=0.134, p=0.409). Realized volatility exhibits a slight negative relationship with margin change (r=-0.171, p=0.291) but essentially no link to revenue growth or ROE change. Relative strength yields weak positive ties to both margin change (r=0.104, p=0.522) and ROE change (r=0.112, p=0.492). All p‑values exceed 0.05, indicating that these associations could easily arise by chance. The lack of significant signals suggests that price dynamics for COLL have not consistently incorporated upcoming changes in its core operating metrics during the observed period.

Price Signals vs Fundamental Outcomes

Collegium Pharmaceutical, Inc. (COLL) — Correlation Heatmap

Institutional Flow vs Price Impact

Collegium Pharmaceutical, Inc. (COLL) — Institutional Flow Analysis

How to read this section: We test whether changes in institutional ownership predict future stock returns. Predictive correlates ownership change at quarter Q with the stock return at quarter Q+1 (do institutions anticipate price moves?). Concurrent correlates both at the same quarter (are institutions reacting to price moves?). If predictive > concurrent, institutional flow is leading; if concurrent dominates, flow is lagging. Institutional ownership data is reported quarterly with limited history, so sample sizes tend to be small.

The institutional flow analysis for Collegium Pharmaceutical (COLL) reveals an ambiguous relationship between fund activity and stock price movements. Both the predictive correlation (r = -0.238, p = 0.145, n = 39) and the concurrent correlation (r = 0.144, p = 0.375, n = 40) fall below conventional thresholds for statistical significance, indicating that institutional trades neither consistently lead nor lag price changes over the observed quarters. Consequently, the data do not support a robust informational advantage for institutions nor a clear momentum-following behavior in this security.

Institutional Flow Metrics

Predictive correlation is negative but not statistically significant (r = -0.238, p > 0.10).
Concurrent correlation is positive yet also insignificant (r = 0.144, p > 0.05).
No clear lead‑lag relationship emerges; institutions appear neither informationally advantaged nor purely momentum‑following for COLL.
Quarterly granularity limits the ability to capture intra‑quarter timing effects.

Limitations: Only 39–40 quarterly observations are available, restricting statistical power. Quarterly institutional flow data lack finer temporal resolution, obscuring short‑term dynamics. Correlation does not imply causation; external market factors may drive both flows and price movements.

COLL

For Collegium Pharmaceutical, the predictive signal is weak and negative (r = -0.2379) with a p‑value of 0.1448 across 39 quarterly observations, suggesting that institutional inflows are not reliably preceding price declines or gains. The concurrent signal is modestly positive (r = 0.1441) but also statistically insignificant (p = 0.375) over 40 quarters, implying that institutional activity tends to move in step with price changes rather than driving them. Given the lack of a clear lead‑lag pattern, investors should treat institutional flow as a non‑deterministic factor for short‑term price direction in COLL.

Earnings Surprise Patterns

Collegium Pharmaceutical, Inc. (COLL) — Earnings Surprise Profile

How to read this section: For each earnings announcement, we measure stock returns in three windows: pre-drift (20 to 1 trading days before — does the market anticipate the surprise?), announcement (day 0 to +1 — the immediate reaction), and post-drift (+2 to +20 days — does the reaction continue or reverse?). Events are classified as positive (>2% EPS surprise), negative (<−2%), or inline. The event study chart shows the average cumulative return path across all events of each type.

Collegium Pharmaceutical has delivered earnings surprises in roughly four out of ten reporting periods, with a beat rate of 40.5% across 42 events. The modest frequency of beats is offset by a pronounced negative average EPS surprise of -10.91%, indicating that when the company misses, it tends to miss by a larger margin than its occasional beats. Revenue surprises are highly volatile, averaging a positive 4031.42%, which reflects the company's reliance on milestone-driven revenue streams that can swing dramatically from quarter to quarter. Return dynamics around earnings releases reveal a weak and negative pre‑announcement drift (pre‑drift correlation = -0.357), suggesting that prior price movements do not reliably foreshadow the direction of the surprise. The announcement reaction is muted for both positive (+9.17%) and negative (-0.11%) EPS surprises, while post‑announcement drifts are modestly opposite in sign, hinting at limited re‑pricing after the event. Overall, the surprise trend is narrowing, implying that recent quarters have shown a slight convergence between consensus estimates and actual outcomes.

Returns by Surprise Direction

Beat rate is low (40.5%) and EPS surprises are on average -10.91%, indicating a tendency toward underperformance.
Pre‑announcement drift correlation (-0.357) is not strong enough to signal reliable information leakage.
Announcement reactions are muted, with post‑announcement drifts only modestly reversing the initial move.
The surprise trend is narrowing, reflecting better consensus alignment in recent periods.

COLL

Collegium’s earnings beat rate of 40.5% signals inconsistent performance relative to analyst forecasts, with no streaks of consecutive beats and a recent miss indicating heightened volatility. The pre‑announcement drift is negative (r = -0.357), but the magnitude falls below the |r|≥0.4 threshold for notable predictive power, so there is little evidence of systematic information leakage in price movements before releases. Announcement reactions are modest—positive surprises generate an average 9.17% jump, while negative surprises barely move the stock (-0.11%)—and post‑drift reversals are small (≈2%), suggesting that markets quickly absorb the disclosed information without prolonged re‑pricing. The narrowing surprise trend points to improving alignment between consensus estimates and actual results, though the underlying EPS bias remains negative.

Earnings Surprise Patterns

Collegium Pharmaceutical, Inc. (COLL) — Event Study

Multi-Signal Integration

Collegium Pharmaceutical, Inc. (COLL) — Signal Coverage

The signal inventory for Collegium Pharmaceutical, Inc. (COLL) reveals a sparse predictive landscape. Across the evaluated dimensions—price-fundamental relationships, institutional behavior, pre‑drift dynamics, and earnings consistency—the company exhibits no notable or strong forward‑looking signals, indicating limited systematic patterns that can be leveraged for forecasting. While data quality is rated strong, coverage remains low, suggesting that the available high‑quality observations are insufficient in breadth to construct robust predictive models.

Collegium Pharmaceutical displays minimal forward‑looking signal strength across all evaluated categories.
Strong data quality is offset by limited coverage, constraining model reliability.
The absence of convergent signals leads to a classification of low overall predictability for COLL.

COLL

Price-fundamental signals show zero instances of notable or strong predictability, and institutional predictive metrics are absent. Pre-drift analyses also fail to generate forward‑looking insights, and earnings consistency is mixed, providing no clear directional bias. Data quality for the existing signals is classified as strong, reflecting reliable source integrity; however, signal coverage is low, meaning few data points exist across the relevant time frames. The convergence of signals is weak—where a modest earnings beat rate of 40% aligns with occasional positive surprises, it does not cohere with any other predictive indicator, resulting in overall low predictability for the stock.

Signal Discovery Summary

Collegium Pharmaceutical, Inc. (COLL) — Summary & Recommendations

The signal discovery exercise applied lagged Pearson correlations across a suite of fundamental, flow and earnings-event variables for Collegium Pharmaceutical (COLL). No statistically notable predictive relationships emerged; the strongest observed correlation was |r|=0.38 with a sample size of 8 quarters, which falls below the predefined relevance threshold of |r|≥0.4. Consequently, the analysis did not identify any leading indicators that consistently forecast price movements for this business. Cross‑company testing also failed to uncover repeatable patterns, suggesting that the current data universe does not support robust multi‑stock predictive rules. Investors should therefore treat any apparent short‑term price signals with caution and rely on broader qualitative assessments until a larger dataset or alternative modeling approach yields clearer insights.

Predictability Rankings

COLL low

No lagged fundamental, flow or earnings‑event variables met the significance criteria for predictive power.

Monitoring Recommendations

Track quarterly YoY changes in revenue and R&D spend as descriptive health metrics, not predictors.
Observe institutional ownership trends for shifts in sentiment that may precede price moves.
Watch upcoming earnings releases for surprise magnitude; large deviations have historically coincided with short‑term volatility.
Maintain awareness of broader sector dynamics (e.g., FDA pipeline approvals) that could influence COLL indirectly.

Key Takeaways

1. The analysis did not identify any statistically strong predictive signals for COLl within the sample constraints.
2. Correlation thresholds were not met, indicating limited lagged explanatory power of the tested variables.
3. Small sample sizes (minimum 8 quarters) reduce confidence in observed relationships and increase susceptibility to regime shifts.
4. Absence of cross‑company patterns suggests that any emergent signals are likely firm‑specific or data‑limited.

The study relies on bivariate Pearson correlations with limited quarterly observations, which constrains statistical power and may miss multivariate effects. Correlations do not imply causation, and identified relationships can be regime dependent; future market conditions or structural changes could invalidate current findings.

COLL

Related Reports

Explore more at Finexus Reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.